Answers are grounded in this paper and cite their sources.
A 1-month-old male infant presented to our emergency department with a 1-week history of nasal discharge and cough, followed by fever onset on day 8 of illness. He was born at 37 weeks and 3 days of gestation, weighing 2700 g, with Apgar scores of 9/9 at 1 and 5 min. He was exclusively formula-fed. At the referring hospital, the infant tested positive for respiratory syncytial virus (RSV) antigen. Laboratory findings showed a WBC count of 8000/μL (Lymphocytes 57.6%, Granulocytes 18.6%, Monocytes 20.9%) and a CRP level of 6.0 mg/dL. The referring physician was concerned about clinical deterioration and the possibility of bacterial superinfection. Upon arrival at our institution, the vital signs were as follows: temperature, 37.2°C; respiratory rate, 52 breaths/min; heart rate, 130 beats/min; SpO2 92% on room air. Physical examination revealed tachypnea without obvious retractions, wet crackles in the bilateral lower lung fields, but no meningeal signs. Additionally, there were no signs and symptoms of heart failure, such as general edema or heart murmurs. Formula intake had decreased from the usual 120 mL per feeding to 30–50 mL per feeding. Chest X-ray demonstrated bilateral hilar prominence with generalized increased bronchovascular markings and some peribronchial thickening, consistent with viral bronchiolitis (Figure 1). Notably, no focal infiltrates or consolidation were observed. Upon closer inspection, there was involvement of the horizontal fissure in the right lung and slightly asymmetric hyperinflation of the lower lobes, with the right lower lobe appearing more radiotransparent than the left (Figure 1, yellow arrow). While these findings were predominantly consistent with viral bronchiolitis, the asymmetric hyperinflation and fissure involvement raised consideration for superimposed bacterial infection. Blood cultures, urine analysis, and urine cultures showed no abnormalities. However, we acknowledge that elevated CRP and poor feeding are nonspecific findings that can occur in severe viral bronchiolitis alone. Given the infant's age, elevated CRP, and clinical signs suggestive of bacterial superinfection, empirical antibiotic therapy was initiated with sulbactam/ampicillin (SBT/ABPC) at 150 mg/kg/day divided into three doses intravenously, selected to cover common neonatal pathogens including Group B Streptococcus, Escherichia coli, and Haemophilus influenzae [3]. After 48 h of SBT/ABPC therapy, the infant achieved fever resolution but continued to exhibit persistent clinical concerns. Formula intake remained poor at 30–50 mL per feeding, and wet cough continued. On hospital day 3, posterior nasopharyngeal culture results revealed the growth of Haemophilus influenzae with β-lactamase production. The isolate was presumed to be non-typeable H. influenzae (NTHi) based on non-mucoid colony morphology on chocolate agar, as mucoid colonies suggestive of encapsulated strains were absent. The organism demonstrated resistance to sulbactam/ampicillin (SBT/ABPC) (minimum inhibitory concentration [MIC] 8 μg/mL), which was unexpected given that beta-lactamase inhibitor combinations typically remain effective against β-lactamase-producing strains (Table 1). The combination of β-lactamase production and sulbactam/ampicillin (SBT/ABPC) resistance (MIC 8 μg/mL) suggests a BLPACR (β-lactamase-producing amoxicillin/clavulanic acid-resistant) mechanism. This indicates that β-lactamase inhibitors cannot overcome the resistance due to altered penicillin-binding proteins (PBPs), particularly PBP3 [5]. The ftsI gene encoding PBP3 contains critical amino acid substitutions that confer β-lactam resistance in β-lactamase-negative ampicillin-resistant (BLNAR) strains [5]. Recent genomic analyses have revealed that mutational resistance mechanisms in H. influenzae are becoming increasingly complex, with multiple amino acid substitutions contributing to β-lactam resistance [6]. Particularly concerning are substitutions near the conserved Lys-Thr-Gly (KTG) and Ser-Ser-Asn (SSN) motifs, which significantly reduce PBP3 affinity for β-lactams [5]. Our institutional surveillance data (Table 2) demonstrate concerning trends in antimicrobial resistance patterns. Statistical analysis revealed a significant increase in BLNAR rates from 2023 to 2024 (21% vs. 45%) compared to other drug-susceptibility patterns (p = 0.001, χ2 test; odds ratio = 3.04, 95% confidence interval: 1.53–6.15), highlighting the clinical relevance of our case. The ABPC susceptibility rate declined from 41% in 2023 to 21% in 2024, with a slight recovery to 27% in the 2025 provisional data. These findings align with global antimicrobial resistance (AMR) trends, where bacterial AMR was associated with 4.95 million deaths worldwide in 2019, with lower respiratory infections accounting for over 1.5 million AMR-associated deaths [7]. In pediatric populations, H. influenzae demonstrates particularly concerning resistance patterns, with Chinese surveillance data showing 58.1% ampicillin resistance, primarily due to β-lactamase production (50.3%), and 9.3% β-lactamase-negative ampicillin-resistant strains [3]. These findings reflect the broader challenge of increasing antibiotic resistance in H. influenzae isolates from pediatric populations worldwide. Given the BLPACR pattern, third-generation cephalosporins (cefotaxime [CTX], ceftazidime [CAZ], cefditoren [CDTR]) or carbapenems (imipenem [IPM], meropenem [MEPM]) represent appropriate alternatives, showing excellent in vitro activity (MIC 0.25–1 μg/mL) [8]. The persistent poor feeding and wet cough, despite fever resolution, suggested inadequate antimicrobial coverage. We changed antibiotic therapy to cefotaxime (CTX) 100 mg/kg/day, divided into two doses intravenously. Following the switch to cefotaxime, a remarkable clinical improvement was observed within 24 h. Formula intake returned to the usual 120 mL per feeding, the wet cough significantly decreased, and overall clinical condition improved markedly. This rapid response pattern, occurring within one bacterial doubling time and preceding the expected RSV resolution by several days, provided suggestive evidence supporting the presence of bacterial superinfection contributing to the clinical syndrome. Cefotaxime was continued for 5 days, after which we transitioned to oral cefdinir (avoiding pivoxil ester-containing antibiotics due to the risk of carnitine deficiency in neonates) and discharged home. Outpatient follow-up confirmed complete clinical recovery. Interpretive limitations: While we acknowledge that nasopharyngeal culture cannot definitively establish lower respiratory tract pathogenicity, the combination of resistant organism detection, clinical deterioration timing, therapeutic response pattern, and temporal correlation suggests a pathogenic role rather than simple colonization. The rapid clinical improvement following targeted antimicrobial therapy provided retrospective validation of our diagnostic hypothesis [1]. Clinical implications: This case suggests that RSV-positive infants who show deterioration after day 7, particularly with elevated CRP and feeding reduction, warrant consideration for bacterial superinfection and empirical therapy guided by local resistance patterns. NTHi, which resides exclusively in human pharynges and is increasingly recognized as pathogens causing both localized respiratory tract infections and systemic infections such as bacteremia and pneumonia [11], warrants particular attention in pediatric respiratory infections. This case highlights the challenges of discovering NTHi vaccine antigens and the limited efficacy of current preventive measures. Future perspectives on RSV prevention: Long-acting monoclonal antibody nirsevimab has demonstrated a 74.5% reduction in medically attended RSV lower respiratory tract infections and a 62.1% reduction in hospitalization [12]. Maternal RSV prefusion F protein vaccination shows 81.8% efficacy against severe RSV lower respiratory tract infection through 90 days of life and 69.4% through 180 days [13]. Real-world data from the United Kingdom confirm effectiveness ranging from 72% to 82.2%, with particularly high protection in preterm infants (89.9%), and large-scale surveillance has found no increase in adverse maternal outcomes [14-16]. As these preventive strategies become widespread, atypical presentations with late deterioration—as in our case—may suggest bacterial superinfection, underscoring ongoing vigilance for antimicrobial resistance. This case highlights the importance of systematic clinical reasoning when managing complex respiratory infections in high-risk neonates. The emergence of multiply-resistant H. influenzae strains with BLPACR mechanisms emphasizes the critical need for microbiological surveillance, culture-directed therapy, and careful clinical correlation. While diagnostic uncertainty regarding the definitive role of nasopharyngeal bacterial isolates persists, the patient's clinical response to targeted antimicrobial therapy based on susceptibility results supported our therapeutic decision in this specific context. Kazumasa Zensho: conceptualization, investigation, writing – original draft, writing – review and editing, methodology. Naoki Nojima: writing – review and editing, investigation, validation. Ryoma Hino: investigation, writing – review and editing. Naohi Isse: supervision, writing – original draft, writing – review and editing. AI Assistance Statement: The authors used DeepL Write for English language editing and expression refinement during manuscript preparation. All scientific content, analysis, and conclusions remain solely the responsibility of the authors. The authors have nothing to report. This case report was conducted in accordance with the principles of the Declaration of Helsinki and did not require institutional review board approval as it involved retrospective analysis of a single clinical case without patient identification. Oral informed consent was obtained from the patient's guardian for publication of this case report. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Zensho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: